Rapid Dose Therapeutics Corp Announces Proposed Equity Private Placement Financing
Rapid Dose Therapeutics Corp (CSE: DOSE) has announced plans for an equity private placement financing to raise up to $5,000,000 in gross proceeds. The financing will consist of up to 20,833,333 common shares priced at $0.24 per share.
The company has engaged Meadowbank Asset Management Inc. as the agent, who will receive a 1% cash commission on proceeds from investors they introduce, plus agent warrants equal to 6% of shares issued to their referred investors. Each agent warrant will be exercisable at $0.33 per share for two years.
The proceeds will be used for debt retirement, research and development, capital expansion, and working capital. The financing may close in multiple tranches, with securities subject to a four-month hold period.
Rapid Dose Therapeutics Corp (CSE: DOSE) ha annunciato piani per un collocamento privato di azioni per raccogliere fino a $5.000.000 in proventi lordi. Il finanziamento consisterà in fino a 20.833.333 azioni ordinarie prezzate a $0,24 per azione.
L'azienda ha incaricato Meadowbank Asset Management Inc. come agente, che riceverà una commissione in contante dell'1% sui proventi degli investitori da loro introdotti, oltre a warrant per agenti pari al 6% delle azioni emesse ai loro investitori referenziati. Ogni warrant per agente sarà esercitabile a $0,33 per azione per due anni.
I proventi saranno utilizzati per estinzione del debito, ricerca e sviluppo, espansione del capitale e capitale circolante. Il finanziamento potrebbe chiudersi in più tranche, con titoli soggetti a un periodo di blocco di quattro mesi.
Rapid Dose Therapeutics Corp (CSE: DOSE) ha anunciado planes para una colocación privada de acciones para recaudar hasta $5,000,000 en ingresos brutos. El financiamiento consistirá en hasta 20,833,333 acciones comunes a un precio de $0.24 por acción.
La empresa ha contratado a Meadowbank Asset Management Inc. como agente, que recibirá una comisión en efectivo del 1% sobre los ingresos de los inversores que presenten, además de warrants para agentes equivalentes al 6% de las acciones emitidas a sus inversores referidos. Cada warrant para agente será ejercitable a $0.33 por acción durante dos años.
Los ingresos se utilizarán para extinción de deudas, investigación y desarrollo, expansión de capital y capital de trabajo. El financiamiento puede cerrarse en múltiples tramos, con valores sujetos a un período de bloqueo de cuatro meses.
Rapid Dose Therapeutics Corp (CSE: DOSE)는 최대 $5,000,000의 총 수익을 올리기 위한 자본 사모 배치 계획을 발표했습니다. 이 자금 조달은 $0.24의 가격으로 최대 20,833,333주의 보통주로 구성됩니다.
회사는 Meadowbank Asset Management Inc.를 에이전트로 위임하였으며, 이들은 소개한 투자자들로부터 발생한 수익의 1% 현금 수수료를 받을 것이며, 그들의 추천 투자자에게 발행된 주식의 6%에 해당하는 에이전트 워런트를 추가로 받게 됩니다. 각 에이전트 워런트는 2년 동안 주당 $0.33에 행사할 수 있습니다.
수익금은 부채 상환, 연구 및 개발, 자본 확장 및 운전 자본에 사용될 것입니다. 자금 조달은 여러 차례에 걸쳐 종료될 수 있으며, 증권은 4개월의 보유 기간이 적용됩니다.
Rapid Dose Therapeutics Corp (CSE: DOSE) a annoncé des plans pour un placement privé d'actions afin de lever jusqu'à $5,000,000 de produits bruts. Le financement se composera de jusqu'à 20.833.333 actions ordinaires au prix de $0,24 par action.
La société a engagé Meadowbank Asset Management Inc. comme agent, qui recevra une commission en espèces de 1 % sur les produits des investisseurs qu'elle présente, ainsi que des bons de souscription d'agents équivalents à 6 % des actions émises à ses investisseurs référés. Chaque bon de souscription d'agent sera exerçable à 0,33 $ par action pendant deux ans.
Les produits seront utilisés pour le remboursement de la dette, la recherche et le développement, l'expansion du capital et le fonds de roulement. Le financement peut se clôturer en plusieurs tranches, avec des titres soumis à une période de blocage de quatre mois.
Rapid Dose Therapeutics Corp (CSE: DOSE) hat Pläne für eine private Platzierung von Eigenkapital bekannt gegeben, um bis zu $5.000.000 an Bruttoerlösen zu erzielen. Die Finanzierung wird aus bis zu 20.833.333 Stammaktien bestehen, die zu einem Preis von $0,24 pro Aktie angeboten werden.
Das Unternehmen hat Meadowbank Asset Management Inc. als Agenten beauftragt, der eine Barprovision von 1% auf die von ihm vorgestellten Investoren erhalten wird, sowie Agenten-Warrants, die 6% der an die von ihnen empfohlenen Investoren ausgegebenen Aktien entsprechen. Jeder Agenten-Warrant kann zwei Jahre lang zu $0,33 pro Aktie ausgeübt werden.
Die Erlöse werden für Schuldentilgung, Forschung und Entwicklung, Kapitalerweiterung und Betriebskapital verwendet. Die Finanzierung kann in mehreren Tranchen abgeschlossen werden, wobei die Wertpapiere einer viermonatigen Haltedauer unterliegen.
- Raising up to $5 million in new capital
- Low agent commission rate of 1% on introduced investors
- Multiple use cases for proceeds including debt reduction and R&D
- Potential shareholder dilution through issuance of up to 20,833,333 new shares
- Additional dilution through agent warrants
- Four-month hold period restricts immediate trading of new shares
Burlington, Ontario--(Newsfile Corp. - February 18, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that it plans to complete an equity private placement financing (the "Financing") for up to
The Company will be engaging Meadowbank Asset Management Inc. (the "Agent") in respect of the Financing. The Agent shall be entitled to be paid a cash commission equal to
The Company intends to use the proceeds from the Financing for debt retirement, research and development, capital expansion and working capital purposes. The Financing may close in one or more tranches. The securities issued on the Financing will be subject to a four-month hold from the applicable date of closing.
About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company's flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. For more information about the Company, visit www.rapid- dose.com.
Contacts:
RDT Investor Contact:
Mark Upsdell, CEO
416-477-1052
investorrelations@rapid-dose.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend", "will", "could", "are planned to", "are expected to" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, statements pertaining to the use of funds from the Financing and the anticipated closing of the Financing, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States. The securities described in this press release have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/241395
FAQ
How much is Rapid Dose Therapeutics (RDTCF) looking to raise in their 2025 private placement?
What is the share price for RDTCF's February 2025 private placement?
How will RDTCF use the proceeds from their 2025 private placement?
What are the terms of the agent warrants in RDTCF's 2025 private placement?
How long is the hold period for shares issued in RDTCF's 2025 private placement?
